Summary of studies for sarcomatoid renal cell cancer
| Author | N | Treatment | Objective response (%) | PFS (months) | OS (months) |
| Sella et al 26 | 8 | Cyclophosphamide+vincristine + doxorubicin+dacarbazine | 25 | NA | 13 |
| Mian et al 27 | 67 | Interferon based therapy | 21 | NA | 19 |
| Escudier et al 28 | 23 | Doxorubicin+ifosfamide | 0 | 2.2 | 3.3 |
| Haas et al 4 | 38 | Gemcitabine+doxorubicin | 15.8 | 3.5 | 8.8 |
| Golshayan et al 29 | 26 | Sunitinib | 19 | 5.3 | 11.8 |
| Kyriakopoulous et al 30 | 230 | VEGF inhibitors | 21 | 4.5 | 10.4 |
| Mckay et al 10 | 16 | Atezolizumab+bevacizumab | 44 | NA | NA |
| McDermott et al 11 | 60 | Ipilimumab+nivolumab | 56.7 | 8.4 | 31.2 |
N, number of patients in the study; NA, not reported; OS, overall survival; PFS, progression-free survival; VEGF, vascular endothelial growth factor.